Loading clinical trials...
Loading clinical trials...
The goal of this clinical trial is to evaluate the safety and effectiveness of a novel diagnostic strategy for prostate cancer, in which men with a moderate risk of prostate cancer are monitored using PSA and MRI instead of immediate biopsy,. The main questions it aims to answer are: * Is it safe to delay biopsy, making sure that clinical significant prostate cancers are not often missed? * Does it reduce unnecessary biopsies and overtreatment?
Age
18 - No limit years
Sex
MALE
Healthy Volunteers
No
Treant
Emmen, Drenthe, Netherlands
Andros Clinics
Arnhem, Gelderland, Netherlands
Radboud University Medical Centre
Nijmegen, Gelderland, Netherlands
Canisius Wilhelmina Hospital
Nijmegen, Gelderland, Netherlands
Antoni van Leeuwenhoek Hospital
Amsterdam, North Holland, Netherlands
Maasstad Hospital
Rotterdam, South Holland, Netherlands
St Antonius Hospital
Nieuwegein, Utrecht, Netherlands
Start Date
May 14, 2025
Primary Completion Date
January 1, 2031
Completion Date
January 1, 2031
Last Updated
December 4, 2025
503
ESTIMATED participants
PSA and MRI-monitoring
OTHER
Lead Sponsor
St. Antonius Hospital
NCT06842498
NCT05691465
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04550494